Quoin Pharmaceuticals, Ltd. (QNRX) intrinsic value & 10-year financials
Quoin Pharmaceuticals, Ltd. (QNRX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.90
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 18.7%
- Free cash flow (FY2025)
- —
QNRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$15.8M | — | — | — | -141.6% |
| FY2024 | — | -$9.0M | — | — | — | -120.6% |
| FY2023 | — | -$8.7M | — | — | — | -132.9% |
| FY2022 | — | -$9.4M | — | — | — | -232.7% |
| FY2021 | — | -$21.5M | — | — | — | 721.4% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Quoin Pharmaceuticals, Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Quoin Pharmaceuticals, Ltd. has historically struggled to out-earn its cost of capital, averaging just -78.0% ROIC.
Quoin Pharmaceuticals, Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Quoin Pharmaceuticals, Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.